Daniel Fells
Medical · Buffalo, NYNPI 1265594840
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,483 and has fallen 99.3% since, to $18 in 2025. Among medical clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$830
- AstraZeneca$650
- Novo Nordisk$527
- GSK$496
- Insulet Corporation$397
- Mylan Specialty L.p.$319
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,278100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $830 |
| AstraZeneca | 30 | $650 |
| Novo Nordisk | 34 | $527 |
| GSK | 32 | $496 |
| Insulet Corporation | 18 | $397 |
| Mylan Specialty L.p. | 15 | $319 |
| Lilly USA, LLC | 22 | $319 |
| Pfizer | 11 | $203 |
| Boehringer Ingelheim | 9 | $165 |
| Bayer | 6 | $160 |
| Amgen | 7 | $149 |
| Mannkind Corporation | 6 | $132 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $82 |
| Scilex Pharmaceuticals Inc. | 5 | $77 |
| Eisai Inc. | 5 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $64 |
| Esperion Therapeutics, Inc. | 3 | $44 |
| Novartis | 2 | $42 |
| Johnson & Johnson | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Dexcom, Inc. | 3 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Exact Sciences | 2 | $33 |
| Lundbeck LLC | 1 | $32 |
| Grifols USA, LLC | 2 | $32 |
| Irhythm Technologies, Inc. | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Indivior Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,287 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 33 | $51,602 |
| JardianceEmpagliflozin | 26 | $31,210 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $30,486 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $25,411 |
| OzempicSemaglutide | 22 | $23,426 |
| JanuviaSitagliptin Phosphate | 22 | $22,022 |
| MounjaroTirzepatide | 13 | $18,081 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $17,799 |
| EliquisApixaban | 20 | $13,158 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $11,954 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,629 |
| KerendiaFinerenone | 11 | $7,116 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 151 | $5,721 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,784 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $650 | $74,18565 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $165 | $67,25088 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $496 | $42,44060 claims |
| Novo NordiskOzempic | $527 | $23,42622 claims |
| Lilly USA, LLCMounjaro, Humalog | $319 | $19,81925 claims |
| PfizerEliquis | $203 | $13,15820 claims |
| BayerKerendia | $160 | $7,11611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.
Other medical in Buffalo
- Lauren WiatrowskiBuffalo$18K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.